Merus Reports Promising Petosemtamab Data in Metastatic Colorectal Cancer

Merus has reported interim data from a phase 2 trial of petosemtamab in metastatic colorectal cancer. The bispecific antibody demonstrated a 100% response rate in first-line left-sided mCRC and a 62% response rate in second-line left- and right-sided mCRC when combined with standard chemotherapy FOLFOX/FOLFIRI. Petosemtamab monotherapy in third-line and beyond showed a well-tolerated safety profile. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.